Literature DB >> 15289404

Treatment of locally advanced breast cancer.

Sunil Verma, Mark Clemons, Barbara Fitzgerald, Orit Freedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15289404      PMCID： PMC490054          DOI： 10.1503/cmaj.1040532

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

Review 1.  Rebuilding a professional practice model. The return of role-based practice accountability.

Authors:  Maria Williams O'Rourke
Journal:  Nurs Adm Q       Date:  2003 Apr-Jun

2.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

3.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

Authors:  Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Ann Brown; Roy Smith; Eleftherios P Mamounas; Bernard Fisher; Richard Margolese; Heather Theoret; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

5.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

6.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

7.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Authors:  R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 8.  Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.

Authors:  Tamara Shenkier; Lorna Weir; Mark Levine; Ivo Olivotto; Timothy Whelan; Leonard Reyno
Journal:  CMAJ       Date:  2004-03-16       Impact factor: 8.262
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.